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ABSTRACT
Rad51 plays a key role in the repair of DNA double-
strand breaks through homologous recombination,
which is the central process in the maintenance of
genomic integrity. Five paralogs of the human
Rad51 gene (hRad51) have been identified to date,
including hRad51B, hRad51C, hRad51D, Xrcc2 and
Xrcc3. In searches of additional hRad51 paralogs,
we identified a novel hRad51 variant that lacked the
sequence corresponding to exon 9 (hRad51-Dex9).
The expected amino acid sequence of hRad51-Dex9
showed a frame-shift at codon 259, which resulted
in a truncated C-terminus. RT-PCR analysis revea-
led that both hRad51 and hRad51-Dex9 were pro-
minently expressed in the testis, but that there were
subtle differences in tissue specificity. The hRad51-
"ex9 protein was detected as a 31-kDa protein in
the testis and localized at the nucleus. In addition,
the hRad51-"ex9 protein showed a DNA-strand
exchange activity comparable to that of hRad51.
Taken together, these results indicate that hRad51-
"ex9 promotes homologous pairing and DNA strand
exchange in the nucleus, suggesting that alternative
pathways in hRad51- or hRad51-"ex9-dependent
manners exist for DNA recombination and repair.
INTRODUCTION
Homologous recombination (HR) is a fundamental pro-
cess conserved in all organisms, maintaining genomic
stability through the repair of exogenous and endogenous
DNA double-strand breaks. HR also contributes to
genomic diversity in evolution through its pivotal roles in
the exchange of chromatids during meiosis (1). In addition,
dysregulation of HR may lead to aberrant genetic
rearrangements and genomic instability, resulting in
translocations, deletions, duplications or loss of hetero-
zygosity (2). Precise control of the HR equilibrium is there-
fore essential for genetic stability because both HR
stimulation and repression lead to genome instability (3).
Rad51, a eukaryotic ortholog of bacterial RecA, plays a
central role in the repair of double-strand DNA breaks by
mediating homologous pairing and strand exchange in
recombinatory structures known as Rad51 foci in the
nucleus (4). Rad51 belongs to the Rad52 epistasis group in
Saccharomyces cerevisiae, which is comprised of a number
of the key genes (Rad50 to Rad57) involved in recombina-
tional repair of double-strand DNA breaks (5). Among the
members of the Rad52 epistasis group, Rad51 shows the
highest degree of sequence conservation in evolution, with
83% amino acid sequence homology between yeast and
human orthologs and 99% homology between mouse and
human orthologs (6). The functional importance of Rad51
has been further emphasized by the ﬁndings that Rad51
interacts with the tumor suppressor protein, p53 (7,8), and
the breast cancer-susceptibility proteins, BRCA1 and
BRCA2 (9–11). Additionally, elevated levels of hRad51
have been observed in a variety of tumor cells (12–14),
suggesting thatstrict regulation of this recombinase maybe
essential for maintaining genome integrity.
To date, ﬁve human Rad51 (hRad51) paralogs, Rad51B
(Rad51L1),Rad51C(Rad51L2),Rad51D(Rad51L3),Xrcc2
and Xrcc3, have been identiﬁed. Each of these genes shows
only a limited degree of sequence similarity to hRad51,
however, they all contain the RecA domain for DNA
recombination and the Walker A and B motifs for ATP
binding and hydrolysis in the predicted amino acid
sequences (15–18). These hRad51 paralogs have presum-
ablyarisenthroughaseriesofgeneduplicationsintheearly
stages of eukaryotic evolution (19). In addition, the
ﬁve hRad51 paralogs have been reported to assist the
DNA strand exchange activity of hRad51, forming two
distinct complexes, Rad51B-Rad51C-Rad51D-Xrcc2 and
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paralogs has been shown to lead to increased sensitivity to
DNA cross-linking agents and ionizing radiation in
vertebrate cells (21–23).
In an attempt to identify additional hRad51 paralogs
in humans, we searched a human testis cDNA library.
We report here a novel splice variant of hRad51, hRad51-
iex9, which lacks the sequence corresponding to exon 9.
Thisnovelvariantwasalsofoundintheexpressedsequence
tag (EST)-databases. The hRad51-iex9 protein was
localized in the nucleus and detected as an expected
molecular weight of 31kDa in the testis. The hRad51-
ex9 protein showed DNA strand exchange activity that
was comparable to that of hRad51, suggesting that this
novel variant also functions as a recombinase. Addi-
tionally, using site-directed mutagenesis, we found that a
short basic motif located in the C-terminus of hRad51-
ex9 may play a functional role in nuclear localization of
this novel variant.
MATERIALS AND METHODS
Identification ofhRad51-Dex9
A human testis 50-stretch cDNA library (Clontech) was
screened using a hRad51 cDNA probe. The cDNA probe
was P
32-labeled by random primer labeling, and hybridiza-
tion was conducted in 50% formamide, 5  SSPE
(1  SSPE: 150mM sodium chloride, 10mM sodium
phosphate, 1mM EDTA, pH 7.4), 10  Denhardt’s
solution, 2% SDS and 100mg/ml denatured salmon
sperm DNA at 428C for 16h. The ﬁlters were washed
twicein2 SSC(1 SSC:150mMsodiumchloride,15mM
sodium citrate, pH 7.0), 0.1% SDS at room temperature
and then twice in 0.2  SSC, 0.1% SDS at 428C. Next, the
ﬁlters were exposed to Kodak XAR ﬁlm at –708C for
varying periods of time. The positive phage clones were
then sequenced using an ABI 310 automated DNA
sequencer. The human EST database was also searched
for identiﬁcation of hRad51 paralogs using the BLASTN
program (http://www.ncbi.nlm.nih.gov/cgi-bin/BLAST).
The EST AI018041 clone was purchased from Open Bio-
systems. The nucleotide sequence reported in this paper will
appear in the GenBank under accession number EU362635.
RT-PCR analysis in human tissues
Human Multiple Tissue cDNA panels (Clontech) were
PCR-ampliﬁed using ExTag polymerase (Takara) with
primers speciﬁc to both hRad51 and hRad51-Dex9 (for-
ward: 50-tttggagaattccgaactgg-30; and reverse: 50-aggaagac
agggagagtcg-30), which were derived from the ﬂanking
regions of exon 9. The reaction mixture was subjected to 30
cyclesof948Cfor30s,588Cfor30sand728Cfor40switha
predenaturation at 948C for 4min and a ﬁnal extension at
728C for 7min. The ampliﬁed PCR products were then
analyzed by electrophoresis on 2.0% agarose gels.
Expression andpurification of therecombinant
hRad51 and hRad51-"ex9 proteins
The full-coding sequences of hRad51 and hRad51-Dex9
were PCR-ampliﬁed from recombinant phage clones using
Pfu DNA polymerase (Stratagene) according to the manu-
facturer’s instructions. The sequences of the oligonucleo-
tide primers are available upon request. A unique
restriction site, either NotI or BamHI, was introduced
intoeachprimertoallowconvenientsubcloning.ThePCR-
ampliﬁed fragments were then gel-puriﬁed and ligated into
pET28b (Novagen) or pET21c (Novagen) at the NotI and
BamHI restriction sites in frame with the C-terminal hexa-
histidine tag. The resulting expression constructs were then
conﬁrmed to contain the desired sequences by DNA
sequence analysis using the BigDye termination version
3.0 (ABI). Among the expression constructs, pET28b-
hRad51 and pET21c-hRad51-ex9 were used for expres-
sion of the hRad51 and hRad51-ex9 proteins,
respectively.
The Escherichia coli strain, BL21 (DE3) (Novagen), was
used for transformation of the pET-derived expression
constructs. The recombinant proteins were expressed and
puriﬁed as previously described (24). However, the
hRad51-ex9 protein resulted in the formation of inclu-
sion bodies. Denaturing and refolding of the hRad51-ex9
protein into an enzymatically active form were done as
previouslypublishedforotherhumanproteins(25).Brieﬂy,
the inclusion bodies were precipitated by centrifugation
at 8000g for 20min and then homogenized in 6M urea,
10mM K2HPO4, pH 8.2 and 3mM b-mercaptoethanol.
The solubilized recombinant proteins were then puriﬁed
using Ni–NTA agarose resins (Qiagen). For refolding, the
denatured hRad51-ex9 protein was ﬁrst dialyzed over-
night against a buﬀer of 10mM K2HPO4, pH 9.6, 200mM
CuCl2 and 2% sodium N-lauroylsarcosinate and then
against a buﬀer of 10mM K2HPO4, pH 9.6 and 5mM
CuCl2. Next, the proteins were further dialyzed twice
against 10mM K2HPO4, pH 7.0. The concentration of the
dialyzed protein samples was then determined using a BCA
Protein Assay Kit (Bio-Rad). All of the puriﬁcation
procedures were conducted at 48C. The purity and size of
the recombinant proteins were assessed by SDS–PAGE.
The puriﬁed recombinant proteins were further conﬁrmed
by western blot analysis using a commercial hRad51
polyclonal antibody (Calbiochem).
DNA strand exchange assays
DNA strand exchange assays were done as previously
described (26,27). Brieﬂy, the recombinant hRad51 or
hRad51-ex9 protein (ﬁnal concentration, 3.5mM) was
mixed with 125ng (ﬁnal concentration, 16.8mM in nucleo-
tides) of fX 174 viral DNA (New England Biolabs) in 20ml
buﬀer containing 20mM HEPES, pH 6.5, 1mM DTT,
6.6mM MgCl2, 3mM ATP, 20mM creatine phosphate,
0.1mg/ml creatine kinase and50mg/mlBSA. After 5minof
incubation at 378C, 120ng (ﬁnal concentration, 8.4mMi n
base pairs) of PstI-linearized fX 174 dsDNA (New
England Biolabs) in 1ml and 1ml of 100mM MgCl2 were
added to the reaction mixture. Following subsequent
incubation for 15, 30, 60, 120 or 240min at 378C, 0.5%
SDS and 0.5mg/ml proteinase K were added to stop the
exchange reaction. The incubated DNA samples were then
run in 0.8% agarose gels. The gels were stained with
0.1mg/ml of syber green (Molecular Probe) for 2h and then
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Photoshop 7.0 (Adobe).
Generationof ahRad51-"ex9-specific polyclonal antibody
A synthetic peptide (EERKRGNQNLQNLRLS) was
covalently conjugated to maleimide-activated keyhole
limpet homocyanin. The peptide conjugate was then
emulsiﬁed with an equal volume of complete Freund’s
adjuvant. Adult rabbits of 1.8–2.0kg in weight were intra-
muscularly injected with 500mg of the emulsiﬁed peptide
conjugate four times at a 2-week interval. The rabbits were
bled on Days 7 and 14 after the last injection, and the
presence of antibodies was then evaluated using an ELISA
assay. The antibodies were then puriﬁed using a Protein A
Agarose Kit (KPL) according to the manufacturer’s
instructions.
Westernblot analysis inhuman tissues
Human tissuespecimens were homogenized in alysis buﬀer
containing 50mM Tris, pH 7.5, 150mM NaCl, 2% SDS,
1mM EDTA, 1mM PMSF, 1mM aprotinin and 1mM
chymostatin. The protein concentrations of the tissue
extracts were determined using a BCA Protein Assay
Kit (Bio-Rad). For western blot analysis, 100mgo f
tissue extracts was subjected to 12.5% SDS–PAGE and
then immunoblotted onto a nitrocellulose membrane
(Amersham Bioscience). The membranes were then
blocked in Tris-buﬀered saline Tween-20 (TBST) contain-
ing 5% skimmed milk for 1h at room temperature, after
which they were incubated with the hRad51-ex9-speciﬁc
antibody, a commercial hRad51 polyclonal antibody
(Calbiochem), or preimmune serum for 1h at room
temperature. The protein bands were visualized using an
ECL detection system (Amersham-Pharmacia Biotech),
and GAPDH was used as an internal control.
Subcellular localization ofhRad51-"ex9
Mammalian expression constructs of hRad51 and hRad51-
Dex9 were generated by PCR-amplifying their full coding
sequences from recombinant phage clones using Pfu DNA
polymerase (Stratagene) according to the manufacturer’s
instructions. The sequences of the oligonucleotide primers
are available upon request. A unique restriction site, either
SacI or BamHI, was introduced into each primer for
convenient subcloning. The PCR-ampliﬁed DNA frag-
ments were then ligated into pEGFP-C1 (BD Biosciences)
in frame with the N-terminal GFP tag. The resulting
constructs were transiently transfected into COS-7 cells
that were maintained in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% fetal bovine serum,
100mg/ml of streptomycin and 100 U/ml of penicillin.
At 4–10h posttransfection, the cells were washed with
phosphate-buﬀered saline (PBS) and then ﬁxed with 4%
paraformaldehyde for 5min at room temperature. The
ﬁxed cells were rinsed twice with PBS, permeabilized by
incubation in 0.2% Triton X-100 for 10min and then
rinsed three times with 0.1% BSA in PBS. Nuclei were
stained with propidium iodide (1:1000) (Molecular
Probes), and confocal microscopic analysis was performed
using a Zeiss LSM510 laser-scanning microscope.
Mutagenesis of hRad51-"ex9
Site-directed mutagenesis was performed using a PCR-
based DpnI-treatment method that has been previously
described (28). Mutagenic primers were designed to create
R264A, K265Q and Del264RK in the amino acid sequence
of hRad51-ex9. The sequences of the oligonucleotide
primers are available upon request. Thermocycling was
conducted using Pfu DNA polymerase (Stratagene)
according to the manufacturer’s suggestions. The creation
of mutations in the hRad51-Dex9 cDNA was conﬁrmed by
sequence analysis using the BigDye termination version 3.0
(BD Biosciences). To construct a C-terminal deletion
mutant of hRad51, the sequence corresponding to codons
1 to 258 of hRad51 was PCR-ampliﬁed using Pfu DNA
polymerase (Stratagene) with the following PCR primers:
forward, 50-ccgagctcgaatggcaatgcagatgcagc-30; and rev-
erse, 50-cgcggatcctcactcatcagcgagtcgcag-30. A unique res-
triction site, either SacI or BamHI, was introduced into
each primer to allow convenient subcloning. The PCR-
ampliﬁed DNA fragments were then ligated into pEGFP-
C1(BDBiosciences)inframewiththeN-terminalGFPtag.
RESULTS
Identification ofhRad51-Dex9
The hRad51 gene is composed of 10 exons that encode a
339-amino acid polypeptide with a calculated molecular
mass of 37kDa. In an eﬀort to identify additional hRad51
paralogs in humans, we searched a human testis cDNA
library using a hRad51 cDNA probe with low stringency
and obtained seven autoradiographically positive phage
recombinants (data not shown). Sequence analysis of the
recombinants revealed that all of the isolated clones were
hRad51 cDNAs. However, one clone that contained a
1661-bp insert showed an exon–intron structure distinct
from that of hRad51, speciﬁcally lacking the sequence
corresponding to exon 9 of hRad51 (Figure 1). This novel
splice variant of hRad51, termed hRad51-Dex9, was also
identiﬁed in searches of the human EST databases (EST
ID number: AI018041). We conducted complete sequen-
cing of EST AI018041 that was obtained from a com-
mercial source and subsequently conﬁrmed that the
hRad51-Dex9 cDNA was identical to AI018041, with the
Figure 1. Schematic diagrams of the mRNA structures of hRad51 and
hRad51-Dex9. Exons are shown as numbered boxes, introns as bold lines.
Hatched boxes indicate the deleted exon in the hRad51-Dex9 mRNA.
‘S’ stands for the start codon, and ‘Asterisk’ for the stop codon.
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30UTR sequences than the EST AI018041 clone.
The 50-UTR of hRad51-Dex9 is at least 299bp, the
coding region is 843bp and the 30-UTR is 469bp. The
deletion of exon 9 causes a frame-shift at codon 259,
which leads to premature termination at codon 281. The
expected amino acid sequence of the hRad51-ex9
protein consists of codons 1 to 258 of hRad51 and 22
‘out of frame’ codons from exon 10, containing the
Walker A and B ATP-binding motifs at residues 127–135
and 218–222, respectively (Figure 2). In addition, a basic
motif that is composed of one lysine and two arginine
residues is located at residues 303–306 of hRad51, and a
similar basic motif is found at residues 264–266 in the
newly created C-terminus of hRad51-ex9 (Figure 2).
RT-PCR ANALYSIS OF HRAD51-"EX9 IN
HUMAN TISSUES
To determine the expression of hRad51 and hRad51-Dex9
in human tissues, RT-PCR analysis was conducted using
primers derived from the ﬂanking regions of exon 9. The
RT-PCR analysis was expected to generate a 467-bp
fragment for hRad51-Dex9 and a 589-bp fragment for
hRad51. DNA-amplicons of the expected sizes correspond-
ing to both hRad51 and hRad51-Dex9 were most promi-
nently detected in the testis (Figure 3). Both PCR
amplicons were also detected, though to lesser extents, in
the skeletal muscle, pancreas, thymus and ovary (Figure 3).
Additionally, the hRad51-speciﬁc amplicon was detected in
the placenta, lung, liver, kidney, spleen and colon tissues,
however, the hRad51-Dex9-speciﬁc-amplicon was not
Figure 2. Alignment of the amino acid sequences of hRad51 and hRad51-ex9. The hRad51 polypeptide sequence is aligned with the predicted
amino acid sequence of hRad51-ex9. The 22 ‘out of frame’ codons are indicated with an underline in the amino acid sequence of hRad51-ex9.
Walker A and B ATP-binding motifs and basic motifs are also indicated.
Figure 3. RT-PCR analysis of hRad51 and hRad51-Dex9 in human tissues. A typical example of RT-PCR analysis of hRad51 and hRad51-Dex9 using
poly(A)
+ RNA obtained from 16 diﬀerent human tissues. The analysis was repeated in triplicate, and GAPDH was used as an internal control.
Nucleic Acids Research, 2008, Vol. 36, No. 10 3229detected in these tissues, suggesting that diﬀerent tissue-
speciﬁcities exist between hRad51 and hRad51-Dex9
(Figure 3).
The DNA strand exchange activity of the
hRad51-"ex9 protein
In an eﬀort to express and purify enzymatically active
forms of the hRad51 and hRad51-ex9 proteins, we
expressed the full coding domain sequences of hRad51 and
hRad51-Dex9 using an E. coli expression system. Upon
induction with 1mM IPTG at 378C, the hexa-histidine
tagged recombinant proteins of both hRad51 and hRad51-
ex9wereexpressedathighlevels.Fractionationofthecell
lysates into diﬀerent cellular compartments, such as
cytoplasmic extracts, periplasmic extracts and inclusion
body fractions, revealed that the recombinant hRad51
protein was present in the soluble fractions. However, the
recombinant hRad51-ex9 protein was expressed within
the inclusion bodies. The insoluble hRad51-ex9 protein
was denatured by urea during puriﬁcation and subse-
quently refolded by stepwise dialysis in the presence of
N-lauroylsarcosinate and Cu
2+. The apparent sizes of the
expressed recombinant proteins were in good agreement
withthededucedmolecularmass,whichwas38kDaforthe
recombinant Rad51 protein and 32kDa for the recombi-
nant hRad51-ex9 protein. The puriﬁed recombinant
proteins were conﬁrmed by western blot analysis using a
commercial human Rad51 antibody (Figure 4A).
To assess the DNA strand exchange activities of
hRad51 and hRad51-ex9, we used the puriﬁed recombi-
nant proteins with circular single-strand DNA (ssDNA)
and linear double-strand DNA (dsDNA) of bacteriophage
fX174. In DNA strand exchange reactions, the circular
ssDNA forms joint molecules with the linear dsDNA
through homologous pairing, and then the joint molecules
are converted into nicked circular forms (Figure 4B). Both
the recombinant hRad51 and hRad51-ex9 proteins
showed the expected joint molecules and nicked circular
forms of fX174 at each of the time-intervals tested.
The intensities of the bands corresponding to the nicked
circular form appeared approximately the same in the
either reactions with hRad51 or hRad51-ex9
(Figure 4C), suggesting that strand exchange activity of
hRad51-ex9 is approximately similar to that of
hRad51at least in vitro. However, the hRad51-ex9
protein showed a signiﬁcantly higher activity than
hRad51 in homologous DNA pairing at all the time-
intervals (Figure 4C). These results are comparable with
the previous ﬁndings on C-terminal deletion mutants of
the E. coli RecA protein, which also showed an enhanced
activity in homologous DNA pairing (29–31).
Westernblot analysis ofhRad51-"ex9in human tissues
To evaluate the expression of hRad51-Dex9 at the protein
level in vivo, we generated a polyclonal antibody against
the peptide sequence speciﬁc to hRad51-ex9. This
hRad51-ex9 polyclonal antibody reacted with the
puriﬁed recombinant hRad51-ex9 protein, but not with
the recombinant hRad51 protein (data not shown).
Human placenta, lung, testis and small intestine tissues
were then tested by western blot analysis. A band with the
expected molecular mass of 31kDa for hRad51-ex9 was
prominently detected in the testis; however, this 31-kDa
band was rarely detected in the other tissues tested
(Figure 5A). We also investigated the expression of
hRad51 and hRad51-ex9 using a commercial antibody
expected to react with both hRad51 and hRad51-ex9.
The 37-kDa hRad51 band was prominently detected in the
testis, but at much lower levels in the placenta, lung and
small intestine (Figure 5B). The 31-kDa band correspond-
ing to hRad51-ex9, however, was detected only in the
testis (Figure 5A). These ﬁndings are consistent with those
of the RT-PCR analysis that also showed prominent
expression of hRad51-Dex9 only in the testis.
Nuclear localization ofhRad51-"ex9
To investigate the cellular localization of hRad51 and
hRad51-ex9, mammalian expression constructs contain-
ing the full coding sequence of hRad51 or hRad51-Dex9 in
frame with the N-terminal GFP tag were transfected into
COS-7 cells. Confocal microscopic analysis of the direct
ﬂuorescence of the fusion proteins displayed subcellular
signals of hRad51 and hRad51-ex9 in the nucleus
(Figure 6Aa and b). In addition, both the hRad51 and
hRad51-ex9 proteins were co-localized with nucleus-
speciﬁc propidium iodide staining, further conﬁrming the
Figure 4. DNA strand exchange activity of hRad51 and hRad51-ex9.
(A) Western blot analysis of the puriﬁed recombinant hRad51 and
hRad51-ex9 protein using a commercial hRad51 antibody. Lane 1,
hRad51; Lane 2, hRad51-ex9. (B) Schematic diagram of DNA strand
exchange between circular ssDNA and linear dsDNA of fX 174.
(C) DNA strand exchange reactions mediated by the puriﬁed
recombinant hRad51 and hRad51-ex9 proteins. After incubation
with 3.5mM of either the hRad51 or hRad51-ex9 protein for a series
of time-intervals (15, 30, 60, 120 and 240min), the DNA was analyzed
by 0.8% agarose gel electrophoresis, followed by staining with Syber
green. When the hRad51 or hRad51-ex9 protein was not included in
the strand-exchange reactions, no bands corresponding to the forms of
joint molecules or nicked circles were detected at 240min of incubation
(the ﬁrst lane in each panel).
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cells (data not shown). However, the mutated hRad51
protein that did not contain the C-terminal region from
codons 259 to 339 was primarily detected in the
cytoplasmic area (Figure 6Ac). Taken together, these
results indicate that the signal for the nuclear localization
of hRad51 may reside in the C-terminus and, furthermore,
that the frame-shifted region of hRad51-ex9 may regain
the residues required for nuclear localization.
A basic motif containing a stretch of lysine and arginine
residues was found at residues 264–266 (RKR) in the
frame-shifted C-terminal region of hRad51-ex9. Similar
types of basic motifs have been known to act as a nuclear
localization signal (NLS) in a number of nuclear proteins
(32,33). To determine, therefore, if this basic motif in the
C-terminus of hRad51-ex9 could function as an NLS,
we generated a series of mutant constructs that harbor a
del254-256RK, R264A or K265Q mutation in the basic
motif. In localization studies conducted using the mutant
constructs, each of the mutated hRad51-ex9 proteins
was primarily detected in the cytoplasmic areas, but rarely
in the nuclei (Figure 6Ba–c). These results strongly suggest
that the basic motif located in the newly created
C-terminal region of hRad51-ex9 may function as a
NLS in nuclear localization of this hRad51 variant.
Figure 5. Detection of hRad51-ex9 in human tissues by western blot
analysis. Approximately 100mg of human placenta, lung, testis and small
intestine tissue extracts were subjected to western blot analysis using
a hRad51-ex9-speciﬁc antibody (A) or a commercial hRad51
antibody (B).
Figure 6. Nuclear localization of hRad51, hRad51-ex9 and C-terminal mutants. (A) Direct ﬂuorescence images of COS-7 cells transfected with
hRad51 (a), hRad51-ex9 (b), or hRad51-delC (c) at a magniﬁcation of  1000. The amino acid sequences of hRad51 and hRad51-ex9 are shown
only from codons 241 to 280, and the frame-shifted region in hRad51-ex9 is underlined. The hRad51-iC mutant does not contain the C-terminal
sequence from codons 259 to 339. (B) Direct ﬂuorescence images of COS-7 cells transfected with hRad51-ex9-K265Q (a), hRad51-ex9-R264A (b),
or hRad51-ex9-Del264_265RK (c) at a magniﬁcation of  1000. The hRad51-ex9-K265Q mutant harbors a substitution of Lys to Gln at codon
265, and the hRad51-ex9-R264A mutant contains a substitution of Arg to Ala at codon 264. The residues mutated in hRad51-ex9-K265Q and
hRad51-ex9-R264A are indicated in blue. In hRad51-ex9-Del264_265RK, Arg-Lys residues at codons 264–265 are deleted.
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Here we present a novel variant of hRad51, hRad51-Dex9,
which aberrantly splices the hRad51 mRNA from exon 8
to exon 10, skipping exon 9. The predicted amino acid
sequence of this novel variant contains a truncated
C-terminus of hRad51, however, it retains the RecA
domain for DNA recombination and the Walker A and B
motifs for ATP binding and hydrolysis. With a puriﬁed
recombinant hRad51-ex9 protein, we showed that this
novel variant is capable of catalyzing DNA strand
exchanges in vitro, although further biochemical charac-
terization would be required to determine the precise
enzymatic properties of this hRad51 variant. In expression
studies, hRad51-ex9 was predominantly detected in the
testis at both the mRNA and protein levels and, further,
the hRad51-ex9 protein was localized in the nucleus.
Taken together, these ﬁndings indicate that hRad51-ex9
catalyzes homologous pairing and DNA-strand exchange
in the nucleus, suggesting that alternative pathways
involving either hRad51 or hRad51-ex9 may exist for
DNA repair and recombination.
Splice variants of other genes involved in DNA repair
and recombination, including Rad52, Rad51D and DMC1,
have been also reported (34–38). The murine and human
Rad52 mRNAs undergo alternative splicing, resulting in
several variants with a truncated C-terminus (34,35).
Rad52 is known to catalyze the replacement of replication
protein A with Rad51 on ssDNA and to promote strand
exchange between complementary ssDNA and dsDNA
(39,40). The human Rad52 variants interacted with both
ssDNA and dsDNA; however, they did not bind to the
full-length human Rad52 due to deletion of the self-
interaction domain (34). Furthermore, the murine Rad52
splice variants increased the frequency of sister chromatid
repair in both mammalian cells and yeast, whereas the
intact murine Rad52 was more likely involved in
homology-directed repair (35). Alternatively spliced
forms of Rad51D and DMC1 in both humans and mice
have been also identiﬁed, but their functional signiﬁcance
has not been evaluated (36–38). However, the presence of
these variants of the proteins involved in HR further
implies the presence of alternative pathways for the
control of recombinational repair of dsDNA breaks.
Rad51 and its paralogs are found in the nucleus,
however, it has not yet been determined if they are
transported independently into the nucleus or through
interactions with other proteins. BRCA2 has been known
to play a critical role in the nuclear transport and foci
formation of Rad51 upon exposure to exogenous damage
(9–11). However, without any exogenous DNA damage,
replication-associated formation of Rad51 foci occurred
in a BRCA2-independent manner in CAPAN-1 cells that
carry a BRCA2 truncation (41), suggesting that distinct
mechanisms may be responsible for the nuclear localiza-
tion and focus formation of Rad51 in the presence or
absence of exogenous DNA-damaging agents. Further,
several hRad51 paralogs have been shown to translocate
into nucleus in a BRCA2-independent manner, using a
basic motif composed of lysines and arginines as a NLS
(42,43). hRad51C contains a basic motif composed of a
short stretch of lysine and arginine residues at the
C-terminus. Using a deletion construct of the C-terminal
region, the basic motif of hRad51C was shown to function
as a NLS for nuclear transport of hRad51C in mammalian
cells (42). In addition, hRad51B that contains a basic
motif at the N-terminus was shown to translocate into the
nucleus in a BRCA2-independent manner (43). hRad51
also contains a basic motif at residues 303–306 (RKGR) in
the C-terminus. This basic motif is deleted in hRad51-
ex9 due to the translational frame-shift. However, in the
frame-shifted C-terminus of hRad51-ex9, a similar basic
motif reappears at residues 264–266 (RKR). Our studies
with oligonucleotide-directed mutagenesis of the RKR
motif in hRad51-ex9 demonstrated that this short basic
motif is required for the nuclear localization of hRad51-
ex9, suggesting that nuclear localization of hRad51-
ex9 may be independent of BRCA2 in the absence of
any DNA-damaging agents, at least in the cultured cells
tested.
Rad51 has been reported to interact with p53 and
BRCA2, both of which play pivotal roles in maintaining
genome integrity. In response to DNA damage, p53
modulates HR through physical interaction with several
proteins implicated in recombination, including Rad51,
Rad54, BLM and WRN (44,45). Using in vitro binding
assays, p53 was reported to interact with the region
between codons 125 and 220 of hRad51 (8). The p53-
interactive region in hRad51 corresponds to the homo-
oligomerization region that is critical for formation of the
functional hRad51 nucleoprotein ﬁlaments (46). The
conservation of the p53-interactive region in hRad51-
ex9 suggests that this novel variant also interacts with
p53, unless the absence of the C-terminal region in
hRad51-ex9 aﬀects the physical interaction with p53.
BRCA2 interacts with Rad51 through the eight conserved
BRC repeats (47,48), and mutations within these repeats
are associated with an increased risk of breast cancer
(49,50). Electron microscopy studies showed that the BRC
repeat 4 interacts with the nucleotide-binding core of
Rad51, whereas the BRC repeat 3 interacts with the
N-terminal region of Rad51, suggesting that the BRC
repeats bind to distinct regions of Rad51 (51). The
BRCA2-interactive region in hRad51 was studied using
yeast two-hybrid and in vitro binding assays, which
revealed that the C-terminus of hRad51 (codons 98–339)
is crucial for interaction with BRCA2 (47). Our ﬁnding
that the C-terminal region (codons 280–389) of hRad51 is
deleted in hRad51-ex9 suggests that this novel variant
may have a diﬀerent binding property from hRad51 in
interaction with BRCA2. Further characterization of the
interactive proﬁle of hRad51-ex9, particularly with p53
and BRCA2, will be necessary to determine the functional
roles that this novel recombinase may play in the
maintenance of genome stability and the elimination of
DNA double-strand breaks.
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